Genenta Science S.p.A.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pierluigi Paracchi
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Via Olgettina No. 58 Milan MI Italy 20132
- IPO Date
- Dec 15, 2021
- CIK
- 0001838716
- Website
- genenta.com
- Similar Companies
- Business
- Genenta Science S.p.A. is a clinical-stage biotechnology company specializing in the development of lentivirus-based gene and cell therapies targeting solid tumors and cancer. Its core products include Temferon, a proprietary hematopoietic stem cell gene therapy designed to treat glioblastoma multiforme and metastatic renal cell cancer. The company utilizes gene-based cytokine delivery technology to activate the immune system within tumors to elicit anti-tumor responses. Genenta operates globally, including significant presence in Italy and the United States, and is headquartered in Milan, Italy. Founded in 2011, Genenta focuses on immuno-oncology and advanced cell-based therapeutics. Recent major developments include an expanded strategic collaboration with Anemocyte to provide an off-the-shelf lentiviral vector plasmid DNA technology platform, enhancing the production capabilities for advanced gene therapy programs. This partnership builds on previous ties and aims to accelerate scalable high-quality plasmid DNA manufacturing critical for gene therapy advancements. Additionally, Genenta secured approximately €20 million (around $22 million) in strategic financing through a mandatory convertible bond with ENEA Tech and Biomedical to support the advancement of Temferon in metastatic renal cell cancer. The company also strengthened its manufacturing and development agreement with AGC Biologics by adding exclusive GMP manufacturing capacity in AGC's Cell and Gene Therapy Center of Excellence, facilitating scale-up for ongoing clinical programs. In late 2025, Genenta completed a $15 million registered direct offering by selling American Depositary Shares (ADS) to fund pipeline expansion efforts. Genenta is positioned in the immuno-oncology and gene therapy sectors, targeting cancer patients requiring novel therapeutic options, with a focus on hematopoietic stem cell therapies for solid tumors. Its partnerships and financial initiatives reflect continued expansion and optimization of its gene and cell therapy platforms for global markets, particularly in the US and Europe. The company's efforts underscore a commitment to innovative, scalable manufacturing and clinical development, aiming to bring transformative treatments to oncology patients worldwide.
Company News
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
Genenta signs Definitive Agreements with Sophia High Tech
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Genenta Science Provides Update on CEO Ownership
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell?
Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates